SCHEMBL7119042

SCHEMBL7119042

O=C(C=CC(=O)OCCCN1CCOCC1)Nc1cc2c(Nc3cc4nn(Cc5ccccc5)cc4c4ccccc34)ncnc2cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 14/20 0.52
ERBB2 P04626 6/20 0.52
JAK3 P52333 3/20 0.46
ERBB4 Q15303 3/20 0.46
AURKA O14965 4/20 0.46
AURKB Q96GD4 3/20 0.46
HDAC3 O15379 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
SRC P12931 2/20 0.43
ROCK2 O75116 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43
RET P07949 1/20 0.43
MET P08581 1/20 0.43
MAPT P10636 1/20 0.43
PDGFRA P16234 1/20 0.43
LTK P29376 1/20 0.43
TTK P33981 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118823 0.91 AURKB (0.47) EGFRERBB2JAK3ERBB4AURKA
SCHEMBL7122291 0.91 EGFR (0.64) EGFRERBB2JAK3ERBB4AURKA
SCHEMBL7122248 0.88 EGFR (0.51) EGFRERBB2JAK3ERBB4AURKA
SCHEMBL7119380 0.87 EGFR (0.50) EGFRERBB2JAK3ERBB4AURKA
SCHEMBL7122208 0.83 EGFR (0.49) EGFRERBB2JAK3ERBB4
SCHEMBL7126239 0.83 EGFR (0.56) EGFRERBB2JAK3ERBB4AURKA
SCHEMBL7242380 0.82 EGFR (0.59) EGFRERBB2JAK3ERBB4AURKA
SCHEMBL7244011 0.81 EGFR (0.65) EGFRERBB2JAK3ERBB4AURKA
SCHEMBL7130766 0.81 EGFR (0.64) EGFRERBB2JAK3ERBB4AURKB
SCHEMBL7125513 0.80 EGFR (0.47) EGFRERBB2JAK3ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases BRIDGES ALEXANDER JAMES (US) 2003-05-08 US claimed
US-6153617-A Irreversible bicyclic inhibitors of tyrosine kinases WARNER-LAMBERT COMPANY (US) 2000-11-28 US claimed
WO-1999006396-A1 IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1999-02-11 WO claimed
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases BRIDGES ALEXANDER JAMES (US) 2003-05-08 US disclosed
US-6153617-A Irreversible bicyclic inhibitors of tyrosine kinases WARNER-LAMBERT COMPANY (US) 2000-11-28 US disclosed
WO-1999006396-A1 IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases ERBB2, ERBB3, LCK EGFR 26/4885ERBB2 1/4885JAK3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.